Halozyme Therapeutics Inc (HALO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Halozyme Therapeutics Inc (HALO) has a cash flow conversion efficiency ratio of 0.354x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($178.60 Million) by net assets ($503.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Halozyme Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Halozyme Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Halozyme Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.
Halozyme Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Halozyme Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
INPOST S.A UNSP.ADR/1/2
F:6690
|
0.256x |
|
Dpm Metals Inc.
AU:DPM
|
0.056x |
|
Zhongfu Shenying Carbon Fiber Co. Ltd. A
SHG:688295
|
N/A |
|
Raia Drogasil S.A
SA:RADL3
|
0.057x |
|
NISSAN MOTOR SP. ADR/2
F:NISE
|
N/A |
|
SHIZUOKA FIN. GROUP INC.
F:P2U
|
N/A |
|
Anhui Yingliu
SHG:603308
|
0.017x |
|
Element Solutions Inc
NYSE:ESI
|
0.038x |
Annual Cash Flow Conversion Efficiency for Halozyme Therapeutics Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Halozyme Therapeutics Inc from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see Halozyme Therapeutics Inc (HALO) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $363.82 Million | $479.06 Million | 1.317x | -71.60% |
| 2023-12-31 | $83.81 Million | $388.57 Million | 4.636x | +227.87% |
| 2022-12-31 | $169.80 Million | $240.11 Million | 1.414x | -6.99% |
| 2021-12-31 | $196.95 Million | $299.44 Million | 1.520x | +314.12% |
| 2020-12-31 | $151.05 Million | $55.45 Million | 0.367x | +139.44% |
| 2019-12-31 | $91.77 Million | $-85.42 Million | -0.931x | -368.05% |
| 2018-12-31 | $248.89 Million | $-49.50 Million | -0.199x | -130.91% |
| 2017-12-31 | $208.37 Million | $134.05 Million | 0.643x | -58.52% |
| 2016-12-31 | $-32.48 Million | $-50.38 Million | 1.551x | +279.86% |
| 2015-12-31 | $43.00 Million | $-37.08 Million | -0.862x | +24.95% |
| 2014-12-31 | $41.35 Million | $-47.52 Million | -1.149x | -146.56% |
| 2013-12-31 | $-19.99 Million | $-49.34 Million | 2.468x | +287.44% |
| 2012-12-31 | $48.85 Million | $-64.33 Million | -1.317x | +58.22% |
| 2011-12-31 | $10.90 Million | $-34.35 Million | -3.151x | -41.31% |
| 2010-12-31 | $20.35 Million | $-45.39 Million | -2.230x | +61.65% |
| 2009-12-31 | $6.90 Million | $-40.15 Million | -5.816x | -152.86% |
| 2008-12-31 | $15.38 Million | $-35.37 Million | -2.300x | -89880.87% |
| 2007-12-31 | $57.77 Million | $-147.66K | -0.003x | -100.83% |
| 2006-12-31 | $23.08 Million | $7.08 Million | 0.307x | +142.97% |
| 2005-12-31 | $18.21 Million | $-13.00 Million | -0.714x | -37.11% |
| 2004-12-31 | $14.82 Million | $-7.72 Million | -0.521x | +89.46% |
| 2003-12-31 | $10.06K | $-49.73K | -4.942x | -669.13% |
| 2002-12-31 | $86.81K | $-55.78K | -0.642x | +57.31% |
| 2001-12-31 | $22.84K | $-34.37K | -1.505x | -- |
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal… Read more